Biotechnology

New data reveals an oral drug can halt severe hereditary angioedema attacks in minutes, promising a future free from needles and fear for thousands.

For 20 years, Montreal's Segal Cancer Centre has quietly built a world-class innovation engine. We dissect its unique model where research, care, and funding converge.

A new partnership between Argonaut and Ensera aims to untangle complex supply chains for drug-device products, potentially leveling the field for smaller innovators.

China's Atom Therapeutics is advancing a dual-threat pipeline, with novel drugs for gout and a groundbreaking anti-inflammatory aimed at cardiovascular disease.

While biopharma braces for Medicare price negotiations, Halozyme claims immunity. Is its tech-licensing model the new blueprint for resilience or just a loophole?

Dr. Aida Habtezion’s leap from Pfizer to the board of Bio Usawa is more than a career move; it’s a key signal in the race to build Africa’s medical independence.

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

Beyond headlines of chip wars, a 30-year partnership between Taiwan's ITRI and Europe is quietly building our future in AI, green energy, and robotics.

Akeso's new breast cancer trial is more than a clinical step; it's a key move in a bold strategy to dominate next-gen cancer therapy and capture a lucrative market.

Stunning new US/EU data for BTK inhibitor orelabrutinib signals a major push into Western markets, challenging established blood cancer therapies.

A Dutch biotech is in late-stage trials for nizubaglustat, a drug targeting rare, fatal neurological disorders. A look at the science, strategy, and hope.

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

New data shows remarkable response rates for epcoritamab in a vulnerable patient group with limited options, signaling a potential paradigm shift in first-line lymphoma care.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

Atossa Therapeutics secures a crucial capital lifeline. We dissect the deal, its impact on a promising cancer drug, and what it reveals about biotech funding today.

As Angel Yeast marks 40 years, its latest sustainability report reveals a strategic pivot towards biotech and ESG, setting a new industry standard.

Australian biotech Gelteq has a gel that makes bitter medicine taste good to dogs. It's more than a pet owner's dream—it's a strategic move in a $47B market.

A landmark deal for CEL-SCI’s cancer drug Multikine in Saudi Arabia isn't just about a new market; it’s a case study in national ambition and biotech finance.

Promising clinical trial results offer hope for cancer patients at risk of permanent, treatment-induced hearing loss, a devastating and common trade-off.